<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOID ADSORBED- clostridium tetani toxoid antigen (formaldehyde inactivated) injection, suspension </strong><br>Sanofi Pasteur Inc.<br></p></div>
<h1><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid<br>Adsorbed</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First">AHFS Category 80:08</p>
<p><span class="Bold">TTOX</span></p>
<p><span class="Bold Italics">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="description"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc., for intramuscular injection, is a sterile suspension of alum-precipitated (aluminum potassium sulfate) toxoid in an isotonic sodium chloride solution. The vaccine, after <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">shaking</span>, is a turbid liquid, whitish-gray in color.</p>
<p><span class="Italics">Clostridium tetani</span> culture is grown in a peptone-based medium containing an extract of bovine muscle tissue and detoxified with formaldehyde. The bovine muscle tissue used in this medium is US sourced. The detoxified material is then purified by serial ammonium sulfate fractionation and diafiltration, followed by sterile filtration. The toxoid is adsorbed to aluminum potassium sulfate (alum). The adsorbed toxoid is diluted with physiological saline solution (0.85%). <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is supplied in a unit dose 0.5 mL vial, which contains a trace amount of thimerosal [(mercury derivative), (≤0.3 μg mercury/dose)] from the manufacturing process. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is also supplied in a 5 mL vial, which contains the preservative thimerosal [(mercury derivative), (25 μg mercury/dose)].</p>
<p>Each 0.5 mL dose is formulated to contain 5 Lf (flocculation units) of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and not more than 0.25 mg of aluminum. The residual formaldehyde content, by assay, is less than 0.02%. The <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid induces at least 2 units of antitoxin per mL in the guinea pig potency test.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> is an <span class="product-label-link" type="condition" conceptid="442562" conceptname="Poisoning">intoxication</span> manifested primarily by neuromuscular dysfunction caused by a potent exotoxin elaborated by <span class="Italics">Clostridium tetani</span>.</p>
<p>Neonatal <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> occurs among infants born under unhygienic conditions to inadequately vaccinated mothers. Vaccinated mothers confer protection to their infants through transplacental transfer of maternal antibody.</p>
<p>Spores of <span class="Italics">C tetani</span> are ubiquitous. Serologic tests indicate that naturally acquired immunity to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin does not occur in the US.<span class="Sup">1</span> Thus, universal primary vaccination, with subsequent maintenance of adequate antitoxin levels by means of appropriately timed boosters, is necessary to protect persons among all age groups. Following adequate immunization with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, it is thought that protection persists for at least 10 years. Protection against disease is due to the development of neutralizing antibodies to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxin. A serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin level of at least 0.01 IU/mL, measured by neutralization assays, is considered the minimum protective level.<span class="Sup">2</span> More recently, a level of ≥0.1 to 0.2 IU/mL has been considered as protective.<span class="Sup">3</span></p>
<p>The efficacy of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. was determined on the basis of an immunogenicity study with a comparison to a serological correlate of protection (0.01 antitoxin units/mL) established by the Panel on Review of Bacterial Vaccines &amp; Toxoids.<span class="Sup">2</span></p>
<p>A <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed For Adult Use vaccine manufactured by Sanofi Pasteur Inc. was administered to a previously unimmunized rural population 6 to 58 years of age. Among 46 persons with serologic evidence for no pre-existing immunity to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, all had titers of 0.01 AU (antitoxin units) or more, one month after the second and third immunizations.</p>
<p>No immunogenicity data are available on concomitant administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. with other US licensed vaccines.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is indicated for active immunization of children 7 years of age or older, and adults, for prevention of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</p>
<p>For immunization of infants and children younger than 7 years of age against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>, refer to the manufacturers' package inserts for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (DTaP) and for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed (For Pediatric Use) (DT).</p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is not to be used for the treatment of active <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> disease. For use of this vaccine for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> prophylaxis in <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management, refer to <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span>.</p>
<p>Persons who have had <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> should still be immunized since this clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> does not always confer immunity.</p>
<p>As with any vaccine, vaccination with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. may not protect 100% of individuals.</p>
<p>If passive protection against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> is required, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Immune Globulin (Human) (TIG) should be used (see <span class="Bold"><a href="#tpwm">DOSAGE AND ADMINISTRATION, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> PROPHYLAXIS IN <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> MANAGEMENT</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of the vaccine, including thimerosal, a mercury derivative, is a contraindication to receipt of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. (See <span class="Bold"><a href="#description">DESCRIPTION</a></span> section.)</p>
<p>It is a contraindication to use this vaccine after <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or other serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> following a previous dose of this vaccine, any other <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine, or any component of this vaccine. Because of uncertainty as to which component of the vaccine may be responsible, no further vaccination with a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> component should be carried out. Alternatively, such individuals may be referred to an allergist for evaluation if further immunizations are to be considered.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">The stopper of the multi-dose vial contains dry natural latex rubber, which may cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> in latex-sensitive individuals.</p>
<p>Except under circumstances of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management (see <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span> section), booster doses of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. should not be administered more frequently than as recommended for Td vaccines (ie, at 11-12 years of age if at least 5 years have elapsed since the last dose of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid-containing vaccine, and every 10 years thereafter).<span class="Sup">4</span> More frequent booster doses may be associated with increased incidence and severity of adverse reactions.<span class="Sup">1</span></p>
<p>Persons who experienced severe Arthus-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> following a prior dose of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid usually have very high serum <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> antitoxin levels and should not be given even emergency doses of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. more frequently than every 10 years, even if they have a <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> that is neither clean nor minor.<span class="Sup">5</span></p>
<p>Because intramuscular injection can cause injection site <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span>, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. should not be given to persons with any <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorder, such as <span class="product-label-link" type="condition" conceptid="4236898" conceptname="Hemophilia">hemophilia</span> or <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, or to persons on anticoagulant therapy unless the potential benefits clearly outweigh the risk of administration. If the decision is made to administer <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. in such persons, it should be given with caution, with steps taken to avoid the risk of <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">hematoma</span> formation following injection.</p>
<p>If Guillain-Barré Syndrome occurs within 6 weeks of receipt of prior vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, the decision to give subsequent doses of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. or any vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid should be based on careful consideration of the potential benefits and possible risks.<span class="Sup">3</span></p>
<p>The Advisory Committee on Immunization Practices (ACIP) has published guidelines for vaccination of persons with recent or acute illness.<span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="general"></a><a name="section-7.1"></a><p></p>
<h2>GENERAL</h2>
<p class="First">Care is to be taken by the health-care provider for the safe and effective use of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc.</p>
<p>EPINEPHRINE INJECTION (1:1000) AND OTHER APPROPRIATE AGENTS AND EQUIPMENT MUST BE IMMEDIATELY AVAILABLE SHOULD AN <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">ACUTE ANAPHYLACTIC REACTION</span> OCCUR DUE TO ANY COMPONENT OF THE VACCINE.</p>
<p>Prior to administration of any dose of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc., the vaccine recipient's current health status and personal health history should be reviewed. This should include a review of the patient's immunization history, any adverse events after previous immunizations and history concerning possible sensitivity to the vaccine and to dry natural latex rubber (contained in the stopper of the multidose vial only), in order to determine the existence of any contraindications to administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. and to allow an assessment of the benefits and risks of vaccination.</p>
<p>Special care should be taken to ensure that the injection does not enter a blood vessel.</p>
<p>Immunocompromised persons (whether from disease or treatment) may not obtain the expected immune response to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc.</p>
<p>Administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is not contraindicated in immunocompromised persons.<span class="Sup">3,6</span></p>
<p>A separate, sterile syringe and needle or a sterile disposable unit should be used for each patient to prevent transmission of blood borne infectious agents. Needles should not be recapped and should be disposed of according to biohazard waste guidelines.</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>INFORMATION FOR PATIENTS</h2>
<p class="First">Prior to administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc., health-care providers should inform the parent, guardian or adult patient of the benefits and risks of immunization.</p>
<p>The health-care provider should inform the parent, guardian or adult patient about the potential for adverse reactions that have been temporally associated with the administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. or other vaccines containing similar components. The parent, guardian or adult patient should be instructed to report any serious adverse reactions to their health-care provider. Adverse events following immunization should be reported by health-care providers to the Vaccine Adverse Event Reporting System (VAERS) (see <span class="Bold"><a href="#reporting">ADVERSE REACTIONS, Reporting of Adverse Events</a></span> section).</p>
<p>As part of the child's or adult's permanent immunization record, the date, lot number and manufacturer of the vaccine administered MUST be recorded.<span class="Sup">7,8,9</span></p>
<p>The health-care provider should inform the parent, guardian or adult patient of the importance of completing the primary immunization series or receiving recommended booster doses, as appropriate.</p>
<p>The health-care provider should provide the Vaccine Information Statements (VISs) which are required by the National Childhood Vaccine Injury Act of 1986 to be given with each immunization.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>DRUG INTERACTIONS</h2>
<p class="First">For information on concomitant administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. with TIG (Human) see <span class="Bold"><a href="#tpwm">DOSAGE AND ADMINISTRATION, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> PROPHYLAXIS IN <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> MANAGEMENT</a></span> section.</p>
<p>Immunosuppressive therapies may reduce the immune response to vaccines (see <span class="Bold"><a href="#general">PRECAUTIONS, GENERAL</a></span> section).</p>
<p>No information is available regarding concomitant administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. with other US licensed vaccines.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY</h2>
<p class="First">No studies have been performed with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. to evaluate carcinogenicity, mutagenic potential, or impact on fertility.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>PREGNANCY CATEGORY C</h2>
<p class="First">Animal reproduction studies have not been conducted with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. It is also not known whether <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. should be given to a pregnant woman only if clearly needed.</p>
<p>The ACIP has published recommendations for immunizing pregnant women against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.<span class="Sup">3</span></p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>NURSING MOTHERS</h2>
<p class="First">It is not known whether <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>PEDIATRIC USE</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is not indicated for infants and children younger than 7 years of age. For immunization of infants and children younger than 7 years of age against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, refer to the manufacturers' package inserts for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids and Acellular <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">Pertussis</span> Vaccine Adsorbed (DTaP) and for <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> and <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoids Adsorbed (For Pediatric Use) (DT).</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>GERIATRIC USE</h2>
<p class="First">The clinical study of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span> Toxoids Adsorbed For Adult Use manufactured by Sanofi Pasteur Inc. did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adversereactions"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions may be local and include <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>, warmth, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4165876" conceptname="Induration">induration</span> with or without <span class="product-label-link" type="condition" conceptid="4082445" conceptname="Tenderness">tenderness</span> as well as <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. <span class="product-label-link" type="condition" conceptid="4272240" conceptname="Malaise">Malaise</span>, transient <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> and <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span> may develop in some patients after the injection. Arthus-type <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span>, characterized by severe local reactions (generally starting 2 to 8 hours after an injection) may occur, particularly in persons who have received multiple prior booster doses of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine.<span class="Sup">5</span></p>
<p>Cases of allergic or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span> (ie, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">hives</span>, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the mouth, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, or <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span>) have been reported after receiving some preparations containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> following vaccine-caused <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> has been reported.<span class="Sup">10</span></p>
<p>Certain neurological conditions have been reported in temporal association with some <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccines. A review by the Institute of Medicine (IOM) concluded that the evidence favors acceptance of a causal relation between <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and both brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span> and Guillian-Barré Syndrome.<span class="Sup">10</span> Other neurological conditions that have been reported include: demyelinating diseases of the central nervous system, peripheral mononeuropathies, cranial mononeuropathies, and EEG disturbances with <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> (with or without permanent intellectual and/or motor function impairment). The IOM has concluded that the evidence is inadequate to accept or reject a causal relation between these conditions and vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid.<span class="Sup">10</span> In the differential diagnosis of polyradiculoneuropathies following administration of a vaccine containing <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid should be considered as a possible etiology.<span class="Sup">10</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="reporting"></a><a name="section-8.1"></a><p></p>
<h2>Reporting of Adverse Events</h2>
<p class="First">The National Vaccine Injury Compensation Program, established by the National Childhood Vaccine Injury Act of 1986, requires physicians and other health-care providers who administer vaccines to maintain permanent vaccination records of the manufacturer and lot number of the vaccine administered in the vaccine recipient's permanent medical record, along with the date of administration of the vaccine, and the name, address, and title of the person administering the vaccine. The Act further requires the health-care professional to report to the US Department of Health and Human Services (DHHS) the occurrence following immunization of any event set forth in the Vaccine Injury Table that occurs within the time period specified or within 7 days, if that is longer, and any contraindicating event listed in the manufacturer's package insert. For <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid, these include <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> or <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> within 7 days; brachial <span class="product-label-link" type="condition" conceptid="444252" conceptname="Neuritis">neuritis</span> within 28 days; an acute complication or sequelae (including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>) of an illness, <span class="product-label-link" type="condition" conceptid="4052648" conceptname="Disability">disability</span>, injury, or condition referred to above; or any events that would contraindicate further doses of vaccine, according to this package insert for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc.<span class="Sup">8,9</span></p>
<p>Reporting by parents, guardians or adult patients of all adverse events after vaccine administration should be encouraged. Adverse events following immunization should be reported by health-care providers to the DHHS Vaccine Adverse Event Reporting System (VAERS). Reporting forms and information about reporting requirements or completion of the form can be obtained from VAERS through a toll-free number 1-800-822-7967.<span class="Sup">7,8,9</span></p>
<p>Health-care providers also should report these events to Pharmacovigilance Department, Sanofi Pasteur Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-2463.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="doseadmin"></a><a name="section-9"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Parenteral drug products should be inspected visually for extraneous particulate matter and/or discoloration prior to administration whenever solution and container permit. (See <span class="Bold"><a href="#description">DESCRIPTION</a></span> section.) If these conditions exist, the vaccine should not be administered.</p>
<p>SHAKE VIAL WELL before withdrawing each dose. Discard vial if vaccine cannot be resuspended.</p>
<p>Before injection, the skin over the site to be injected should be cleansed with a suitable germicide.</p>
<p>Inject intramuscularly in the area of the vastus lateralis (mid-thigh laterally) or deltoid. The vaccine should not be injected into the gluteal area or areas where there may be a major nerve trunk.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.1"></a><p></p>
<h2>Primary Immunization</h2>
<p class="First">For persons 7 years of age and older who have not been immunized previously against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, the primary immunization series of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. consists of three 0.5 mL doses. The intervals between doses recommended by the ACIP are 4 to 8 weeks between the first and second dose, and 6 to 12 months between the second and third dose.<span class="Sup">1</span></p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. may be used to complete the primary immunization series for <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> in children 7 years of age or older who have received one or two doses of whole-cell <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span> DTP, DTaP, and/or DT vaccine. However the safety and efficacy of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. in such children have not been evaluated.</p>
<p>Interruption of the recommended schedule with a delay between doses should not interfere with the final immunity achieved with <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. There is no need to start the series over again, regardless of the time elapsed between doses.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.2"></a><p></p>
<h2>Routine Booster Immunization</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is approved for booster immunization in persons 7 years of age and older who have completed primary immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</p>
<p>Booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> is recommended by the ACIP in persons 11-12 years of age if at least 5 years have elapsed since the last dose of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> and <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> toxoid-containing vaccine.<span class="Sup">4</span> Subsequent routine booster immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> is recommended every 10 years.<span class="Sup">4,11</span> If a dose of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing vaccine is given sooner than 10 years, as part of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management or on exposure to <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span>, the next booster is not needed for 10 years thereafter.<span class="Sup">1</span> MORE FREQUENT BOOSTER IMMUNIZATION AGAINST <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> IS NOT RECOMMENDED AND MAY BE ASSOCIATED WITH INCREASED INCIDENCE AND SEVERITY OF ADVERSE REACTIONS.<span class="Sup">1,3</span> (See <span class="Bold"><a href="#warnings">WARNINGS</a></span> section).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="tpwm"></a><a name="section-9.3"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> PROPHYLAXIS IN <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> MANAGEMENT</h2>
<p class="First">The need for active immunization with a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing preparation, with or without passive immunization with TIG (Human) depends on both the condition of the <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> and the patient's vaccination history (<span class="Bold"><a href="#table1">TABLE 1</a></span>).</p>
<p>A thorough attempt must be made to determine whether a patient has completed primary immunization. Persons who have completed primary immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, and who sustain <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> which are minor and uncontaminated, should receive a booster dose of a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing preparation only if they have not received <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid within the preceding 10 years. For <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> prone <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> (eg, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> contaminated with dirt, feces, soil, and saliva; puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>; avulsions; and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> resulting from missiles, crushing, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, and <span class="product-label-link" type="condition" conceptid="441487" conceptname="Frostbite">frostbite</span>), a booster is appropriate if the patient has not received a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing preparation within the preceding 5 years. If a booster dose is given sooner than 10 years as part of <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management, the next routine booster should not be given for 10 years thereafter.<span class="Sup">1</span></p>
<p>Persons who have not completed primary immunization against <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, or whose immunization history is unknown or uncertain, should be immunized with a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing product. Completion of primary immunization thereafter should be ensured. In addition, if these persons have sustained a <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-prone <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span>, the use of TIG (Human) is recommended. TIG (Human) should be administered at a separate site, with a separate needle and syringe, according to the manufacturer's package insert. If a contraindication to using <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid-containing preparations exists in a person who has not completed a primary immunizing course of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid and other than a clean, minor <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> is sustained, only passive immunization with TIG (Human) should be given.<span class="Sup">1</span></p>
<p><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is approved for <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management in patients 7 years of age and older.</p>
<a name="table1"></a><table width="100%">
<caption><span>TABLE 1<span class="Sup">1</span> SUMMARY GUIDE TO <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> PROPHYLAXIS IN ROUTINE <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">WOUND</span> MANAGEMENT, FOR PERSONS 7 YEARS OF AGE AND OLDER<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th class="Lrule" align="center">History of Adsorbed <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span></th>
<th align="center" colspan="2"><span class="Underline">Clean, Minor <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span></span></th>
<th class="Rrule" align="center" colspan="2"><span class="Underline">All Other <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">Wounds</span><a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a></span></th>
</tr>
<tr class="Last">
<th class="Lrule" align="center">Toxoid (Doses)</th>
<th align="center">Td<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</th>
<th align="center">TIG</th>
<th align="center">Td<a href="#footnote-3" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">TIG</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Important details are in the text of the <span class="Bold"><a href="#doseadmin">DOSAGE AND ADMINISTRATION</a></span> section.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Such as, but not limited to, <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> contaminated with dirt, feces, soil, and saliva; puncture <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>; avulsions; and <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span> resulting from missiles, crushing, <span class="product-label-link" type="condition" conceptid="4022094" conceptname="Thermal burn">burns</span>, and <span class="product-label-link" type="condition" conceptid="441487" conceptname="Frostbite">frostbite</span>.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>Td is preferred by the ACIP to <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid alone to enhance <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">diphtheria</span> protection. <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. is approved for <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> management in persons 7 years of age or older.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>If only three doses of fluid <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span> toxoid have been received, then a fourth dose of toxoid, preferably an adsorbed toxoid should be given.</dd>
<dt><a name="footnote-5" href="#footnote-reference-5">¶</a></dt>
<dd>Yes, if &gt;10 years since last dose.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">#</a></dt>
<dd>Yes, if &gt;5 years since last dose. (More frequent boosters are not needed and can accentuate side effects.)</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td class="Lrule" align="left">Unknown or &lt; three</td>
<td align="center">Yes</td>
<td align="center">No</td>
<td align="center">Yes</td>
<td class="Rrule" align="center">Yes</td>
</tr>
<tr class="Last">
<td class="Lrule" align="left">≥ Three<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a>
</td>
<td align="center">No<a name="footnote-reference-5" href="#footnote-5" class="Sup">¶</a>
</td>
<td align="center">No</td>
<td align="center">No<a name="footnote-reference-6" href="#footnote-6" class="Sup">#</a>
</td>
<td class="Rrule" align="center">No</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-9.4"></a><p></p>
<h2>CONCOMITANT VACCINE ADMINISTRATION</h2>
<p class="First">No safety and immunogenicity data are available on the concomitant administration of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid Adsorbed manufactured by Sanofi Pasteur Inc. with other US licensed vaccines.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Vial (latex-free), 1 Dose (10 per package) – Product No. 49281-820-10<br>Vial, 5 mL – Product No. 49281-800-83</p>
<p>CPT® Code: 90703<br>CPT is a registered trademark of the American Medical Association.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-10.1"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 2° to 8°C (35° to 46°F). DO NOT FREEZE.</p>
</div>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="section-11"></a><p></p>
<h1>REFERENCES</h1>
<ol class="Arabic">
<li>Centers for Disease Control and Prevention (CDC). <span class="product-label-link" type="condition" conceptid="434568" conceptname="Diphtheria">Diphtheria</span>, <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>, and <span class="product-label-link" type="condition" conceptid="257778" conceptname="Pertussis">pertussis</span>: recommendations for vaccine use and other preventive measures: recommendations of the Immunization Practices Advisory Committee (ACIP). <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 1991;40(RR-10):1-28.</li>
<li>Department of Health and Human Services, Food and Drug Administration. Biological products; bacterial vaccines and toxoids; implementation of efficacy review; proposed rule. <span class="Italics">Federal Register.</span> December 13, 1985;50(240):51002-51117.</li>
<li>CDC. General recommendations on immunization. Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP). <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 2002;51(RR-2):1-36.</li>
<li>CDC. Recommended childhood and adolescent immunization schedule–United States, 2005. <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 2005;53(51):Q1-3.</li>
<li>CDC. Update on adult immunization recommendations of the Advisory Committee on Immunization Practices (ACIP). <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 1991;40(RR-12):1-52.</li>
<li>CDC. Use of vaccines and immune globulins in persons with altered immunocompetence. <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 1993;42(RR-4):18.</li>
<li>CDC. Vaccine Adverse Event Reporting System–United States. <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 1990;39(41):730-733.</li>
<li>CDC. National Childhood Vaccine Injury Act: requirements for permanent vaccination records and for reporting of selected events after vaccination. <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 1988;37(13):197-200.</li>
<li>Food and Drug Administration. New reporting requirements for vaccine adverse events. <span class="Italics">FDA Drug Bull.</span> 1988;18(2):16-18.</li>
<li>Institute of Medicine (IOM). Stratton KR, Howe CJ, Johnston RB Jr, eds. <span class="Italics">Adverse Events Associated with Childhood Vaccines: Evidence Bearing on Causality.</span> Washington, DC: National Academy Press; 1994:67-117.</li>
<li>CDC. Recommended adult immunization schedule–United States, October 2004-September 2005. <span class="Italics">MMWR Morb Mortal Wkly Rep.</span> 2004;53(45):Q1-4.</li>
</ol>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<p class="First">Manufactured by:<br>Sanofi Pasteur Inc.<br>Swiftwater PA 18370 USA</p>
<p>Product information<br>as of December 2005</p>
<p><span class="Bold">sanofi pasteur</span></p>
<p>5237</p>
<p>373 3105079</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5 mL Vial Label</h1>
<p class="First">NDC <span class="Bold">49281-820-10</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span><br>Toxoid<br>Adsorbed</span></p>
<p><span class="Bold">TTOX<br>1 Dose<br>(0.5 mL)</span></p>
<p><span class="Italics">Rx only</span></p>
<p><span class="Italics">Preservative-free</span></p>
<p>Mfd by: <span class="Bold">Sanofi Pasteur Inc.</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5 mL Vial Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=669abb62-e995-48f1-a80d-e954f9192fa5&amp;name=<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-01.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 10 Vial Carton</h1>
<p class="First">NDC <span class="Bold">49281-820-10</span></p>
<p><span class="Bold">TTOX</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid<br>Adsorbed</span></p>
<p><span class="Bold">10 </span> VIALS<br><span class="Bold">1</span> Dose<br>each</p>
<p><span class="Bold Italics">Preservative-free</span></p>
<p><span class="Bold"><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">Tetanus</span> Toxoid should not be used<br>for the treatment of <span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>.</span></p>
<p><span class="Italics">Rx only</span></p>
<p><span class="Bold">sanofi pasteur</span></p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 10 Vial Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=669abb62-e995-48f1-a80d-e954f9192fa5&amp;name=<span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">tetanus</span>-02.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOID ADSORBED 		
					</strong><br><span class="contentTableReg">clostridium tetani toxoid antigen (formaldehyde inactivated) injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-820</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">5 [Lf]  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM</strong></td>
<td class="formItem">0.25 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FORMALDEHYDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>THIMEROSAL</strong></td>
<td class="formItem">0.3 ug  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-820-10</td>
<td class="formItem">10  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.5 mL in 1 VIAL</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103913</td>
<td class="formItem">09/23/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong><span class="product-label-link" type="condition" conceptid="435740" conceptname="Tetanus">TETANUS</span> TOXOID ADSORBED 		
					</strong><br><span class="contentTableReg">clostridium tetani toxoid antigen (formaldehyde inactivated) injection, suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">VACCINE LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:49281-800</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</strong> (CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)) </td>
<td class="formItem">CLOSTRIDIUM TETANI TOXOID ANTIGEN (FORMALDEHYDE INACTIVATED)</td>
<td class="formItem">5 [Lf]  in 0.5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ALUMINUM</strong></td>
<td class="formItem">0.25 mg  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FORMALDEHYDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>THIMEROSAL</strong></td>
<td class="formItem">25 ug  in 0.5 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:49281-800-83</td>
<td class="formItem">1  in 1 PACKAGE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA103913</td>
<td class="formItem">09/23/2005</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Sanofi Pasteur Inc.
							(086723285)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Sanofi Pasteur Inc.</td>
<td class="formItem"></td>
<td class="formItem">086723285</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>49bb9a4c-f387-4f3d-8c2f-12977314b8ec</div>
<div>Set id: 669abb62-e995-48f1-a80d-e954f9192fa5</div>
<div>Version: 1</div>
<div>Effective Time: 20120804</div>
</div>
</div> <div class="DistributorName">Sanofi Pasteur Inc.</div></p>
</body></html>
